Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q3 2023 Earnings Call Transcript

Pete Enderlin: And if I can qualify that a little bit in terms of drilling down. Do you see different levels of interest depending on the types of cancer or also since there are varying side effects in a lot of these treatments, does it vary somewhat by the type of modality like chemo, RNA, immunotherapy or whatever? Or is it pretty much across the board?

Dr. David Mazzo: I would say it’s reasonably distributed. The interest is reasonably distributed among people who are either developing new cytotoxics or already marketing chemotherapeutics or immunotherapeutics. We even had discussions with radiopharmaceutical companies, companies that have antisense products, even companies with cellular therapies and nanoparticles. So I think there’s a broad level of interest because the mechanism of action of LSTA1 in theory should help all of those better target solid tumors and infiltrate those tumors. So I think that…

Pete Enderlin: And also reduce side effects, I guess, is an important part of it as well because they’re…

Dr. David Mazzo: I don’t know if it will reduce side effects. I want to be very careful what we say. That would be wonderful. But what we will say is that the evidence to-date shows that LSTA1 will not increase the side effects of those agents. So you should get better efficacy with the same level of side effects. Normally to get better efficacy, we increase concentration and that leads to greater side effects. So I think we’re going to be able, but I wouldn’t say that we eliminate side effects, we’re not so far along that.

Pete Enderlin: Okay. No. And then just one quick one for Kristen. Did you mention the number or the percentage of enrollment so far in the BOLSTER trial, I didn’t get it if you did.

Dr. Kristen Buck: No, I did not. The BOLSTER trial recently opened and we’re early in enrollment.

Operator: [Operator Instructions] And there are no further questions. This concludes the question-and-answer session. I will now turn the call back to Dr. Mazzo for closing remarks.

Dr. David Mazzo: Well, again, thank you all for participating in today’s call. We look forward to speaking with you again during our next quarterly conference call and to continuing to provide updates on our achievements and progress. We remain grateful for your continued interest and support. Stay well and have a good evening.